Showing results (451-460 of 528) with videos related to
Sort By:
Pageof 53
Acta Oncologica (Stockholm, Sweden)|May 19, 2025
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohortFabio Marazzi, Valeria Masiello, Alessandra Fabi, et al.Plos One|November 14, 2019
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approachAlessio Bruni, Niccolò Giaj-Levra, Patrizia Ciammella, et al.NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.NPJ Breast Cancer|August 16, 2025
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysisLetizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, et al.Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.Future Oncology (London, England)|June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK studyFranco Antonio, Luisa Carbognin, Ida Paris, et al.Communications Biology|February 27, 2020
Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigensAlessio Grimaldi, Ilenia Cammarata, Carmela Martire, et al.Oncogene|August 13, 2022
Loss of FGFR4 promotes the malignant phenotype of PDACSabrina D'Agosto, Francesco Pezzini, Lisa Veghini, et al.Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.Journal of Cachexia, Sarcopenia and Muscle|October 23, 2024
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational studyIlaria Trestini, Lorenzo Belluomini, Alessandra Dodi, et al.Pageof 53